Letter to the Editor

Lynn Estes; Robert Orenstein

doi:10.1016/j.clinthera.2007.02.010

Letter to the Editor

Lynn Estes, Robert Orenstein

Infectious Diseases

Research output: Contribution to journal › Letter › peer-review

4 Scopus citations

Original language	English (US)
Pages (from-to)	381-383
Number of pages	3
Journal	Clinical therapeutics
Volume	29
Issue number	2
DOIs	https://doi.org/10.1016/j.clinthera.2007.02.010
State	Published - Feb 2007

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)

Access to Document

10.1016/j.clinthera.2007.02.010

Cite this

@article{5c72b16097b649ccae2c9bfa3338bf03,

title = "Letter to the Editor",

author = "Lynn Estes and Robert Orenstein",

note = "Funding Information: Of concern is the fact that there were numerous important potential conflicts of interest associated with the paper by Mullins et al. 1 One of the authors was an employee of Pfizer Inc., which was also the sponsor of both the Mullins paper and the study on which the decision analysis was based, z Additionally, there were significant unpublished conflicts of interest. For example, the lead author has received -$1 million in grant money from Pfizer/Pharmacia (noted in his publicly available curriculum vitaeS), as well as funding from Pfizer for numerous fellowship contracts. It is of concern that these significant potential conflicts were omitted from the paper, particularly given that this author is an editor of Clinical Therapeutics. Copyright: Copyright 2011 Elsevier B.V., All rights reserved.",

year = "2007",

month = feb,

doi = "10.1016/j.clinthera.2007.02.010",

language = "English (US)",

volume = "29",

pages = "381--383",

journal = "Clinical therapeutics",

issn = "0149-2918",

publisher = "Excerpta Medica",

number = "2",

}

TY - JOUR

T1 - Letter to the Editor

AU - Estes, Lynn

AU - Orenstein, Robert

N1 - Funding Information: Of concern is the fact that there were numerous important potential conflicts of interest associated with the paper by Mullins et al. 1 One of the authors was an employee of Pfizer Inc., which was also the sponsor of both the Mullins paper and the study on which the decision analysis was based, z Additionally, there were significant unpublished conflicts of interest. For example, the lead author has received -$1 million in grant money from Pfizer/Pharmacia (noted in his publicly available curriculum vitaeS), as well as funding from Pfizer for numerous fellowship contracts. It is of concern that these significant potential conflicts were omitted from the paper, particularly given that this author is an editor of Clinical Therapeutics. Copyright: Copyright 2011 Elsevier B.V., All rights reserved.

PY - 2007/2

Y1 - 2007/2

UR - http://www.scopus.com/inward/record.url?scp=34247507251&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247507251&partnerID=8YFLogxK

U2 - 10.1016/j.clinthera.2007.02.010

DO - 10.1016/j.clinthera.2007.02.010

M3 - Letter

AN - SCOPUS:34247507251

SN - 0149-2918

VL - 29

SP - 381

EP - 383

JO - Clinical therapeutics

JF - Clinical therapeutics

IS - 2

ER -

Letter to the Editor

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this